// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Differential gray matter connectivity correlates of CSF biomarkers: results from the EPAD cohort

Luigi Lorenzini - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Impaired default mode network along with increased functional connectivity of the medial temporal lobe as a function of CSF p-Tau/Ab42 ratio in cognitively unimpaired individuals

José María González-de-Echávarri - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Neuroimaging-Derived Phenotypes in the European Prevention of Alzheimer Dementia (EPAD) Cohort Study

Luigi Lorenzini - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

Prediction of amyloid pathology in cognitively unimpaired individuals using structural MRI

Irene Cumplido-Mayoral - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Synergistic effects of CSF Aβ42 and p-Tau on functional resting-state connectivity in cognitively unimpaired individuals

Raffaele Cacciaglia - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The interactive effect of MCI subtype and white-matter hyperintensity load on the expression of large-scale neurofunctional networks

Matteo De Marco - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

Alzheimer's disease detection using explainable AI on PET images

Jack Weatheritt - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Atrophy patterns in sporadic and genetic behavioral variant frontotemporal dementia reflect brain network architecture

Golia Shafiei - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Frontotemporal dementia

N/A

Automatic Brain Extraction using Deep Learning

Jack Weatheritt - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Data-driven evidence for three distinct patterns of amyloid-β accumulation

Lyduine E. Collij - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Neuroinflammation, amyloid, NFT markers and initial cognitive status predict cognitive decline in MCI patients

Fangda Leng - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

18F-flutemetamol

Neuroinflammation in medial temporal regions predicts cognitive decline in dementia with Lewy bodies

Maura Malpetti - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Lewy body dementia

N/A

Quantitative Amyloid PET in the AMYPAD Diagnostic and Patient Management Study

Christopher Buckley - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

18F-flutemetamol

Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals

Lyduine E. Collij - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Residual approaches to capture resilience and resistance in aging and Alzheimer’s disease: A meta-analysis

Diana I. Bocancea - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Web application for single-case AD subtyping and staging based on SuStaIn model

Damiano Archetti - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Alzheimer's disease

N/A

Cardiovascular and dementia risk scores and their association with dementia-related biomarkers in a memory clinic population

Anna Rosenberg - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

Evaluation of blood pressure and cognitive function using individual participant data meta-analysis: the Life-course Blood Pressure cognition (LCBP-COG) study

Ying Xu - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Co-designing toolkits to improve post-diagnostic support for people living with dementia, care partners and health and social care professionals (COGNISANCE)

Jane Wilcock - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dementia

N/A

Distance assessment of cognitive deficits in older immigrants

Marina Boccardi - Alzheimer's Association International Conference (AAIC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved